Why the study?
Does the combination of admission troponin T and ST-segment resolution at 60 min improve early risk stratification for one-year mortality in patients with fibrinolytic-treated STEMI?
Does the combination of admission troponin T and ST-segment resolution at 60 min improve early risk stratification for one-year mortality in patients with fibrinolytic-treated STEMI?
The combination of admission troponin T and ST-segment resolution at 60 minutes provides additive prognostic information for one-year mortality in STEMI patients treated with fibrinolytics.
May aid early risk stratification in fibrinolytic-treated STEMI; hypothesis-generating and requires prospective validation before guiding care.
AIMS: The prognostic value of admission troponin T (tnT) levels and the resolution of the ST-segment elevation in ST-elevation myocardial infarction (STEMI) is well established. However, the combination of these two early available markers for predicting risk has not been evaluated. METHODS AND RESULTS: We evaluated 516 patients with fibrinolytic treated STEMI from the ASSENT-2 and ASSENT-PLUS studies, which had both admission tnT and ST-monitoring available. We used a prospectively defined cut-off value of tnT of 0.1microg/l. For ST-segment resolution, a cut-off of 50% measured after 60min was used. Both a tnT >/=0.1microg/l (n=116) and ST-segment resolution <50% (n=301) were related to higher one-year mortality, 13% vs 4% (P<0.001) and 8.4% vs 2.8% (P=0.009), respectively. In a multivariate analysis ST-segment resolution was and tnT showed a strong trend to be independently related to mortality. The combination of both further improved risk stratification. The one-year mortality in the group with elevation of tnT and without ST-segment resolution compared to the group without tnT elevation and with ST-segment resolution was 18.2% vs 2.8% (P<0.001). CONCLUSIONS: Both tnT on admission and ST-segment resolution after 60min are strong predictors of one-year mortality. The combination of both gives additive early information about prognosis and further improves risk stratification.
No takes yet. Share an insight, caveat, or question.
Erland Björklund (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: